New drug duo fights tough ovarian cancer
NCT ID NCT03462342
Summary
This study tested whether combining two oral drugs, AZD6738 and olaparib, was safe and effective for women whose ovarian cancer had returned. It involved 123 women with a specific type of recurrent ovarian cancer, grouping them based on how their cancer responded to previous platinum-based chemotherapy. The main goals were to find the safest dose and see how well the combination controlled the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE SEROUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.